Curium Pharma, a developer, manufacturer, and distributor of nuclear medicine, has acquired Eczacıbaşı-Monrol Nuclear ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...

How innovation, advanced manufacturing, and expertise drive success in the evolving CDMO and generics landscape.

BSI’s goal is to make QS-21 accessible to a wider range of vaccines and populations, particularly in low-income countries.

National Resilience Inc., a technology-focused biomanufacturing company, is initiating the next phase of its growth in the ...

Linearis has inaugurated a new laboratory in the greater Quebec City region and introduced its high-throughput metabolomics ...

Balancing safety and convenience, innovative stick pack designs offer a patient-centric solution for on-the-go dosage forms.

The formulation comparison between a biosimilar and a branded biologic. The cost, availability, and supply chain benefits of ...

The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Navigating compliance challenges and technology solutions under DSCSA.

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...